The company is transitioning HemaXellerate and related programs from preclinical development into human clinical trials. The product pipeline includes HemaXellarate (autologous stromal vascular fraction from adipose tissue), dCellVax (autologous dendritic cell therapy), tCellVax, DiffronC, and DuroCAR (CAR-T cells).
Cyborg Score Rationale
As of March 31, 2026, the company had $271 in cash against current liabilities of $5.6M, with management explicitly noting substantial doubt about the company's ability to continue as a going concern. Over the past 12 months, the stock lost 97.6%.
Top Insights
Extreme financial distress: $271 cash at Q1 2026 against $5.6M liabilities; going concern warning issued
Heavily diluted capital structure: 232M shares issued in 6 months (H1 2026) for debt conversion
Early-stage pipeline with no approved products; all candidates in preclinical to Phase I/II stages
Revenue model is minimal ($118K in H1 2026); dependent on equity financing and licensing arrangements
Named Competitors
Juno Therapeutics CAR-T — CAR-T cell immunotherapy for oncology